Axatilimab
- Generic Name
- Axatilimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2155851-88-8
- Unique Ingredient Identifier
- R96Z451BMC
- Background
Axatilimab is under investigation in clinical trial NCT04301778 (Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-embolization for Patients With Intrahepatic Cholangiocarcinoma).
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Evaluate a Single-Dose Subcutaneous Axatilimab Compared With Intravenous Axatilimab in Healthy Participants
- First Posted Date
- 2024-12-03
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 72
- Registration Number
- NCT06713590
- Locations
- 🇺🇸
Celerion, Inc, Tempe, Arizona, United States
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
Phase 2
Recruiting
- Conditions
- Chronic Graft-versus-host-disease
- Interventions
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 120
- Registration Number
- NCT06388564
- Locations
- 🇺🇸
Froedtert & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸Mayo Clinic Hospital, Phoenix, Arizona, United States
🇺🇸City of Hope Medical Center, Duarte, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath